Psicopatologie e dipendenze
Dipendenze
- Cannabidiol reduces cigarette consumption in tobacco smokers (PubMed)
- Inhibition of monoacylglycerol lipase enzyme reduces nicotine withdrawal (PubMed)
- Cannabidiol inhibits the reward-facilitating effect of morphine (PubMed)
- Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances (PubMed)
- Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats (PubMed)
- Impact of Cannabis Use during Stabilization on Methadone Maintenance Treatment(PubMed)
- Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010 (PubMed)
- Dysregulation of cannabinoid CB1 receptor and associated signaling networks in brains of cocaine addicts and cocaine-treated rodents (PubMed)
- Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity (PubMed)
- Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder (ScienceDirect)
- Cannabidiol for the treatment of cannabis withdrawal syndrome (PubMed)
- Cannabis use disorders are comparatively prevalent among nonwhite racial/ethnic groups and adolescents: a national study (PubMed)
Disturbi bipolari
- Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential (PubMed)
- Cannabidiol was ineffective for manic episode of bipolar affective disorder (PubMed)
Depressione
- Endocannabinoid system dysfunction in mood and related disorders (PubMed)
- Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa (PubMed)
- The endocannabinoid system and the treatment of mood and anxiety disorders (PubMed)
- Endocannabinoid signaling in the etiology and treatment of major depressive illness(PubMed)
- Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors (PubMed)
- Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants (PubMed)
- Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa (PubMed)
- Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress (PubMed)
- Serum contents of endocannabinoids are correlated with blood pressure in depressed women (PubMed)
- The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants (PubMed)
- Antidepressants and Changes in Concentration of Endocannabinoids and N-Acylethanolamines in Rat Brain Structures (PubMed)
Disturbi dell’umore
- Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders (PubMed)
- The endocannabinoid system and the treatment of mood and anxiety disorders (PubMed)
- The endocannabinoid system and psychiatric disorders (PubMed)
- The endocannabinoid system in the regulation of emotions throughout lifespan: A discussion on therapeutic perspectives (PubMed)
- Endocannabinoid system dysfunction in mood and related disorders (PubMed)
- Effects of cannabidiol (CBD) on regional cerebral blood flow (PubMed)
Schizofrenia
- Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug (PubMed)
- Cannabidiol as a potential treatment for psychosis (PubMed)
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia (PubMed)
- Medical use of cannabis. Cannabidiol: A new light for schizophrenia? (PubMed)
- A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation (PubMed)
- Peripheral endocannabinoid system dysregulation in first-episode psychosis (PubMed)
- Cannabinoids and schizophrenia: Therapeutic prospects (PubMed)
- Antipsychotic-like effects of cannabidiol and rimonabant: Systematic review of animal and human studies (PubMed)
- Cannabidiol monotherapy for treatment-resistant schizophrenia (PubMed)
- Cannabis with high cannabidiol content is associated with fewer psychotic experiences(PubMed)
- Marijuana compound treats schizophrenia with few side effects: Clinical trial (Time)
- Clearing the smoke: what do we know about adolescent cannabis use and schizophrenia?(PubMed)